Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient's age and prostate volume.
age
cancer detection rate
nomogram
prostate cancer
prostate volume
transrectal prostate biopsy
Journal
Research and reports in urology
ISSN: 2253-2447
Titre abrégé: Res Rep Urol
Pays: England
ID NLM: 101576971
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
3
4
2019
pubmed:
3
4
2019
medline:
3
4
2019
Statut:
epublish
Résumé
The aim of this study is to evaluate the efficacy of two different Nara Urological Research and Treatment Group (NURTG) nomograms allocating 6-12 biopsy cores based on age and prostate volume. From April 2006 to July 2014, a total of 1,605 patients who underwent initial prostate biopsy were enrolled. Based on a nomogram taking the patient's age and prostate volume into consideration, 6-12 biopsy cores were allocated. Two types of nomogram were used, for the former group (before March 2009) and latter group (March 2009 onward). Cancer detection rates in all patients and those with prostate-specific antigen values in the gray zone (4.0-10 ng/mL) were compared. Predictive parameters for detection of prostate cancer in gray-zone patients were also investigated. The cancer detection rates in all patients and those in the gray zone were 48% and 38% in the former group and 54% and 41% in the latter group, respectively. The cancer detection rate in all patients was significantly higher in the latter group compared with the former group, but detection in gray-zone patients did not show a significant difference between the two groups ( The latter nomogram provided more acceptable detection rates of clinically significant and insignificant cancer than the former one, and we consider that an initial maximum 12-core transrectal ultrasound-guided needle biopsy may be sufficient for prostate cancer diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study is to evaluate the efficacy of two different Nara Urological Research and Treatment Group (NURTG) nomograms allocating 6-12 biopsy cores based on age and prostate volume.
MATERIALS AND METHODS
METHODS
From April 2006 to July 2014, a total of 1,605 patients who underwent initial prostate biopsy were enrolled. Based on a nomogram taking the patient's age and prostate volume into consideration, 6-12 biopsy cores were allocated. Two types of nomogram were used, for the former group (before March 2009) and latter group (March 2009 onward). Cancer detection rates in all patients and those with prostate-specific antigen values in the gray zone (4.0-10 ng/mL) were compared. Predictive parameters for detection of prostate cancer in gray-zone patients were also investigated.
RESULTS
RESULTS
The cancer detection rates in all patients and those in the gray zone were 48% and 38% in the former group and 54% and 41% in the latter group, respectively. The cancer detection rate in all patients was significantly higher in the latter group compared with the former group, but detection in gray-zone patients did not show a significant difference between the two groups (
CONCLUSION
CONCLUSIONS
The latter nomogram provided more acceptable detection rates of clinically significant and insignificant cancer than the former one, and we consider that an initial maximum 12-core transrectal ultrasound-guided needle biopsy may be sufficient for prostate cancer diagnosis.
Identifiants
pubmed: 30937289
doi: 10.2147/RRU.S193933
pii: rru-11-061
pmc: PMC6430996
doi:
Types de publication
Journal Article
Langues
eng
Pagination
61-68Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
J Urol. 2003 Jan;169(1):130-5
pubmed: 12478120
J Urol. 2005 Oct;174(4 Pt 1):1256-60; discussion 1260-1; author reply 1261
pubmed: 16145388
Int J Urol. 2006 Jan;13(1):10-4
pubmed: 16448425
J Urol. 2006 May;175(5):1605-12
pubmed: 16600713
Prostate Cancer Prostatic Dis. 2007;10(3):274-8
pubmed: 17339878
Eur Urol. 2007 Dec;52(6):1560-3
pubmed: 17532115
Hinyokika Kiyo. 2007 Jul;53(7):459-65
pubmed: 17702178
Eur Urol. 2008 Sep;54(3):601-11
pubmed: 18207312
J Endourol. 2010 Jan;24(1):143-7
pubmed: 20001330
Eur Urol. 2010 Dec;58(6):831-5
pubmed: 20800964
Cancer. 2011 Mar 15;117(6):1210-9
pubmed: 20960520
Eur Urol. 2015 Sep;68(3):438-50
pubmed: 25480312
Eur Urol. 2016 Jan;69(1):149-56
pubmed: 25862143
J Endourol. 2015 Oct;29(10):1115-21
pubmed: 25897467
BMC Res Notes. 2015 Nov 18;8:689
pubmed: 26581414
J Urol. 1989 Jul;142(1):71-4; discussion 74-5
pubmed: 2659827
Res Rep Urol. 2017 Sep 21;9:187-193
pubmed: 29034221
Br J Urol. 1995 Mar;75(3):347-53
pubmed: 7537604
J Urol. 1998 Mar;159(3):920-4
pubmed: 9474183